Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
Carapezzi William R JRExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 32,769 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004032 · doc4.xml · derivative · entry 7 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,769 Underlying: Common Stock · 32,769 shares Expires 2028-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
Carapezzi William R JRExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 37,925 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004032 · doc4.xml · derivative · entry 6 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,925 Underlying: Common Stock · 37,925 shares Expires 2026-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
Carapezzi William R JRExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 27,222 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004032 · doc4.xml · derivative · entry 5 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,222 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
Carapezzi William R JRExecutive Vice President
|
Tax withholdingCommon Stock | 17,618 | $34.76 | $612,401.68 |
DisclosureSEC source: 0001225208-21-004032 · doc4.xml · nonDerivative · entry 3 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,952 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
Carapezzi William R JRExecutive Vice President
|
Tax withholdingCommon Stock | 2,983 | $33.82 | $100,885.06 |
DisclosureSEC source: 0001225208-21-004032 · doc4.xml · nonDerivative · entry 2 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,570 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
Carapezzi William R JRExecutive Vice President
|
Exercise / conversionCommon Stock | 27,222 | $22.89 | $623,111.58 |
DisclosureSEC source: 0001225208-21-004032 · doc4.xml · nonDerivative · entry 1 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 182,050 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · derivative · entry 6 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,050 Underlying: Common Stock · 182,050 shares Expires 2028-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 210,697 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · derivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,697 Underlying: Common Stock · 210,697 shares Expires 2026-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 163,334 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · derivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 163,334 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 105,707 | $34.76 | $3,674,375.32 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,656 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 28,221 | $33.82 | $954,434.22 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,363 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionCommon Stock | 163,334 | $22.89 | $3,738,715.26 |
DisclosureSEC source: 0001225208-21-004033 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 136,537 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004041 · doc4.xml · derivative · entry 8 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,537 Underlying: Common Stock · 136,537 shares Expires 2028-02-25 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 158,023 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004041 · doc4.xml · derivative · entry 7 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,023 Underlying: Common Stock · 158,023 shares Expires 2026-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Hwang AngelaGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 22,686 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004041 · doc4.xml · derivative · entry 6 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,686 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Hwang AngelaGroup President
|
Tax withholdingCommon Stock | 14,682 | $34.76 | $510,346.32 |
DisclosureSEC source: 0001225208-21-004041 · doc4.xml · nonDerivative · entry 3 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,325 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Hwang AngelaGroup President
|
Tax withholdingCommon Stock | 3,920 | $33.82 | $132,574.40 |
DisclosureSEC source: 0001225208-21-004041 · doc4.xml · nonDerivative · entry 2 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,007 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Hwang AngelaGroup President
|
Exercise / conversionCommon Stock | 22,686 | $22.89 | $519,282.54 |
DisclosureSEC source: 0001225208-21-004041 · doc4.xml · nonDerivative · entry 1 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 182,050 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004042 · doc4.xml · derivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,050 Underlying: Common Stock · 182,050 shares Expires 2028-02-25 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 210,697 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004042 · doc4.xml · derivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,697 Underlying: Common Stock · 210,697 shares Expires 2026-02-25 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 28,271 | $33.82 | $956,125.22 |
DisclosureSEC source: 0001225208-21-004042 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,568 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 49,153 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004043 · doc4.xml · derivative · entry 2 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,153 Underlying: Common Stock · 49,153 shares Expires 2028-02-25 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:01 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 56,888 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004043 · doc4.xml · derivative · entry 1 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,888 Underlying: Common Stock · 56,888 shares Expires 2026-02-25 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 32,769 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004051 · doc4.xml · derivative · entry 7 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,769 Underlying: Common Stock · 32,769 shares Expires 2028-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 37,925 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004051 · doc4.xml · derivative · entry 6 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,925 Underlying: Common Stock · 37,925 shares Expires 2026-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 37,658 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004051 · doc4.xml · derivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,658 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 24,371 | $34.76 | $847,135.96 |
DisclosureSEC source: 0001225208-21-004051 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,144 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 6,422 | $33.82 | $217,192.04 |
DisclosureSEC source: 0001225208-21-004051 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,515 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 37,658 | $22.89 | $861,991.62 |
DisclosureSEC source: 0001225208-21-004051 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 106,195 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004052 · doc4.xml · derivative · entry 7 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,195 Underlying: Common Stock · 106,195 shares Expires 2028-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 122,907 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004052 · doc4.xml · derivative · entry 6 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,907 Underlying: Common Stock · 122,907 shares Expires 2026-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 99,816 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004052 · doc4.xml · derivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,816 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 64,599 | $34.76 | $2,245,461.24 |
DisclosureSEC source: 0001225208-21-004052 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,247 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 17,246 | $33.82 | $583,259.72 |
DisclosureSEC source: 0001225208-21-004052 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,846 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionCommon Stock | 99,816 | $22.89 | $2,284,788.24 |
DisclosureSEC source: 0001225208-21-004052 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 72,820 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004053 · doc4.xml · derivative · entry 5 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,820 Underlying: Common Stock · 72,820 shares Expires 2028-02-25 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 84,279 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004053 · doc4.xml · derivative · entry 4 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,279 Underlying: Common Stock · 84,279 shares Expires 2026-02-25 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 14,227 | $33.82 | $481,157.14 |
DisclosureSEC source: 0001225208-21-004053 · doc4.xml · nonDerivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,500 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantCommon Stock | 26,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004053 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,727 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SAHNI PAYALExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 49,153 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004056 · doc4.xml · derivative · entry 7 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,153 Underlying: Common Stock · 49,153 shares Expires 2028-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SAHNI PAYALExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 56,888 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004056 · doc4.xml · derivative · entry 6 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,888 Underlying: Common Stock · 56,888 shares Expires 2026-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SAHNI PAYALExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 9,982 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004056 · doc4.xml · derivative · entry 5 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,982 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SAHNI PAYALExecutive Vice President
|
Tax withholdingCommon Stock | 6,460 | $34.76 | $224,549.60 |
DisclosureSEC source: 0001225208-21-004056 · doc4.xml · nonDerivative · entry 3 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,292 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SAHNI PAYALExecutive Vice President
|
Tax withholdingCommon Stock | 1,197 | $33.82 | $40,482.54 |
DisclosureSEC source: 0001225208-21-004056 · doc4.xml · nonDerivative · entry 2 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,752 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SAHNI PAYALExecutive Vice President
|
Exercise / conversionCommon Stock | 9,982 | $22.89 | $228,487.98 |
DisclosureSEC source: 0001225208-21-004056 · doc4.xml · nonDerivative · entry 1 SAHNI PAYAL · CIK 0001817124 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 57,649 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · derivative · entry 7 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,649 Underlying: Common Stock · 57,649 shares Expires 2028-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 66,721 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · derivative · entry 6 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,721 Underlying: Common Stock · 66,721 shares Expires 2026-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 81,667 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,667 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 52,853 | $34.76 | $1,837,170.28 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,575 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 15,335 | $33.82 | $518,629.70 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,428 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.